---
layout: default
title: EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment
---

# EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2512.14019" class="toolbar-btn" target="_blank">üìÑ arXiv: 2512.14019v1</a>
  <a href="https://arxiv.org/pdf/2512.14019.pdf" class="toolbar-btn" target="_blank">üì• PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2512.14019v1" onclick="toggleFavorite(this, '2512.14019v1', 'EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment')" title="Ê∑ªÂä†Âà∞Êî∂ËóèÂ§π">‚òÜ Êî∂Ëóè</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">üîó ÂàÜ‰∫´</button>
</div>


**‰ΩúËÄÖ**: Juseung Yun, Sunwoo Yu, Sumin Ha, Jonghyun Kim, Janghyeon Lee, Jongseong Jang, Soonyoung Lee

**ÂàÜÁ±ª**: cs.LG, q-bio.QM

**ÂèëÂ∏ÉÊó•Êúü**: 2025-12-16

---

## üí° ‰∏ÄÂè•ËØùË¶ÅÁÇπ

**EXAONE Path 2.5ÔºöÂ§öÁªÑÂ≠¶ÂØπÈΩêÁöÑÁóÖÁêÜÂ≠¶Âü∫Á°ÄÊ®°ÂûãÔºåÁî®‰∫éÊõ¥ÂÖ®Èù¢ÁöÑËÇøÁò§ÁîüÁâ©Â≠¶ÁêÜËß£**

üéØ **ÂåπÈÖçÈ¢ÜÂüü**: **ÊîØÊü±‰∫åÔºöRLÁÆóÊ≥ï‰∏éÊû∂ÊûÑ (RL & Architecture)** **ÊîØÊü±‰πùÔºöÂÖ∑Ë∫´Â§ßÊ®°Âûã (Embodied Foundation Models)**

**ÂÖ≥ÈîÆËØç**: `ÁóÖÁêÜÂ≠¶` `Â§öÊ®°ÊÄÅÂ≠¶‰π†` `ÁªÑÂ≠¶Êï∞ÊçÆ` `ËÇøÁò§ÁîüÁâ©Â≠¶` `ÂØπÊØîÂ≠¶‰π†` `ÂÖ®ÂàáÁâáÂõæÂÉè` `Á≤æÂáÜËÇøÁò§Â≠¶`

## üìã Ê†∏ÂøÉË¶ÅÁÇπ

1. Áé∞ÊúâÁóÖÁêÜÂ≠¶Ê®°Âûã‰∏ªË¶Å‰æùËµñÂõæÂÉè‰ø°ÊÅØÔºåÂøΩÁï•‰∫ÜÂü∫Âõ†ÁªÑÂ≠¶Á≠âÂÖ∂‰ªñÁîüÁâ©Â±ÇÈù¢ÁöÑ‰ø°ÊÅØÔºåÈôêÂà∂‰∫ÜÂØπËÇøÁò§ÁîüÁâ©Â≠¶ÁöÑÂÖ®Èù¢ÁêÜËß£„ÄÇ
2. EXAONE Path 2.5ÈÄöËøáÂ§öÊ®°ÊÄÅËûçÂêàÔºåËÅîÂêàÂª∫Ê®°ÁªÑÁªáÂ≠¶„ÄÅÂü∫Âõ†ÁªÑÂ≠¶„ÄÅË°®ËßÇÂü∫Âõ†ÁªÑÂ≠¶ÂíåËΩ¨ÂΩïÁªÑÂ≠¶Êï∞ÊçÆÔºåÊûÑÂª∫Êõ¥ÂÖ®Èù¢ÁöÑÊÇ£ËÄÖË°®ÂæÅ„ÄÇ
3. ÂÆûÈ™åË°®ÊòéÔºåËØ•Ê®°ÂûãÂú®ÂÜÖÈÉ®‰∏¥Â∫äÊï∞ÊçÆÈõÜÂíåPatho-BenchÂü∫ÂáÜÊµãËØï‰∏≠ÂùáË°®Áé∞Âá∫Ëâ≤ÔºåÂ±ïÁé∞‰∫ÜÈ´òÊï∞ÊçÆÊïàÁéáÂíåÈÄÇÂ∫îÊÄß„ÄÇ

## üìù ÊëòË¶ÅÔºà‰∏≠ÊñáÔºâ

ÁôåÁóáÁöÑËøõÂ±ïÊ∫ê‰∫éÂ§ö‰∏™ÁîüÁâ©Â±ÇÈù¢ÁöÑÁõ∏‰∫í‰ΩúÁî®ÔºåÁâπÂà´ÊòØÂΩ¢ÊÄÅÂ≠¶‰πãÂ§ñ‰ª•ÂèäÂõæÂÉèÊ®°ÂûãÊó†Ê≥ïÊçïÊçâÁöÑÂàÜÂ≠êÂ±ÇÈù¢„ÄÇ‰∏∫‰∫ÜÊçïÊçâÊõ¥ÂπøÊ≥õÁöÑÁîüÁâ©ÂõæÊôØÔºåÊàë‰ª¨ÊèêÂá∫‰∫ÜEXAONE Path 2.5Ôºå‰∏Ä‰∏™ÁóÖÁêÜÂ≠¶Âü∫Á°ÄÊ®°ÂûãÔºåÂÆÉËÅîÂêàÂª∫Ê®°ÁªÑÁªáÂ≠¶„ÄÅÂü∫Âõ†ÁªÑÂ≠¶„ÄÅË°®ËßÇÂü∫Âõ†ÁªÑÂ≠¶ÂíåËΩ¨ÂΩïÁªÑÂ≠¶Ê®°ÊÄÅÔºå‰∫ßÁîü‰∏Ä‰∏™ÁªºÂêàÁöÑÊÇ£ËÄÖË°®ÂæÅÔºåÊõ¥ÂÖ®Èù¢Âú∞ÂèçÊò†ËÇøÁò§ÁîüÁâ©Â≠¶„ÄÇÊàë‰ª¨ÁöÑÊñπÊ≥ïÂåÖÂê´‰∏â‰∏™ÂÖ≥ÈîÆÁªÑÊàêÈÉ®ÂàÜÔºöÔºà1ÔºâÂ§öÊ®°ÊÄÅSigLIPÊçüÂ§±ÔºåÊîØÊåÅË∑®ÂºÇÊûÑÊ®°ÊÄÅÁöÑÊâÄÊúâÊàêÂØπÂØπÊØîÂ≠¶‰π†ÔºõÔºà2ÔºâÁâáÊÆµÊÑüÁü•ÊóãËΩ¨‰ΩçÁΩÆÁºñÁ†ÅÔºàF-RoPEÔºâÊ®°ÂùóÔºåÂú®WSI‰∏≠‰øùÁïôÁ©∫Èó¥ÁªìÊûÑÂíåÁªÑÁªáÁâáÊÆµÊãìÊâëÔºõÔºà3ÔºâWSIÂíåRNA-seqÁöÑÈ¢ÜÂüü‰∏ìÁî®ÂÜÖÈÉ®Âü∫Á°ÄÊ®°ÂûãÔºå‰∏∫Á®≥ÂÅ•ÁöÑÂ§öÊ®°ÊÄÅÂØπÈΩêÊèê‰æõÁîüÁâ©Â≠¶Âü∫Á°ÄÁöÑÂµåÂÖ•„ÄÇÊàë‰ª¨Âú®‰∏§‰∏™‰∫íË°•ÁöÑÂü∫ÂáÜ‰∏äËØÑ‰º∞‰∫ÜEXAONE Path 2.5Ôºå‰∏Ä‰∏™ÊòØÂÜÖÈÉ®ÁúüÂÆû‰∏¥Â∫äÊï∞ÊçÆÈõÜÔºåÂè¶‰∏Ä‰∏™ÊòØÊ∂µÁõñ80‰∏™‰ªªÂä°ÁöÑPatho-BenchÂü∫ÂáÜÔºåÂπ∂‰∏éÂÖ≠‰∏™È¢ÜÂÖàÁöÑÁóÖÁêÜÂ≠¶Âü∫Á°ÄÊ®°ÂûãËøõË°å‰∫ÜÊØîËæÉ„ÄÇÊàë‰ª¨ÁöÑÊ°ÜÊû∂Â±ïÁ§∫‰∫ÜÈ´òÊï∞ÊçÆÂíåÂèÇÊï∞ÊïàÁéáÔºåÂú®Patho-Bench‰∏äÂÆûÁé∞‰∫Ü‰∏éÊúÄÂÖàËøõÁöÑÂü∫Á°ÄÊ®°ÂûãÁõ∏ÂΩìÁöÑÊÄßËÉΩÔºåÂêåÊó∂Âú®ÂÜÖÈÉ®‰∏¥Â∫äÁéØÂ¢É‰∏≠Ë°®Áé∞Âá∫ÊúÄÈ´òÁöÑÈÄÇÂ∫îÊÄß„ÄÇËøô‰∫õÁªìÊûúÁ™ÅÂá∫‰∫ÜÁîüÁâ©‰ø°ÊÅØÂ§öÊ®°ÊÄÅËÆæËÆ°ÁöÑ‰ª∑ÂÄºÔºåÂπ∂Âº∫Ë∞É‰∫ÜÁî®‰∫é‰∏ã‰∏Ä‰ª£Á≤æÂáÜËÇøÁò§Â≠¶ÁöÑÊï¥ÂêàÂü∫Âõ†ÂûãÂà∞Ë°®ÂûãÂª∫Ê®°ÁöÑÊΩúÂäõ„ÄÇ

## üî¨ ÊñπÊ≥ïËØ¶Ëß£

**ÈóÆÈ¢òÂÆö‰πâ**ÔºöÁé∞ÊúâÁóÖÁêÜÂ≠¶Âü∫Á°ÄÊ®°Âûã‰∏ªË¶Å‰æùËµñ‰∫éÁªÑÁªáÁóÖÁêÜÂ≠¶ÂõæÂÉèÔºåÂøΩÁï•‰∫ÜÂü∫Âõ†ÁªÑÂ≠¶„ÄÅË°®ËßÇÂü∫Âõ†ÁªÑÂ≠¶ÂíåËΩ¨ÂΩïÁªÑÂ≠¶Á≠âÂÖ∂‰ªñÈáçË¶ÅÁöÑÁîüÁâ©‰ø°ÊÅØ„ÄÇËøôÂØºËá¥Ê®°ÂûãÊó†Ê≥ïÂÖ®Èù¢ÁêÜËß£ËÇøÁò§ÁöÑÂ§çÊùÇÁîüÁâ©Â≠¶Êú∫Âà∂ÔºåÈôêÂà∂‰∫ÜÂÖ∂Âú®Á≤æÂáÜËÇøÁò§Â≠¶‰∏≠ÁöÑÂ∫îÁî®„ÄÇÁé∞ÊúâÊñπÊ≥ïÈöæ‰ª•ÊúâÊïàÂú∞ËûçÂêàËøô‰∫õÂºÇÊûÑÊï∞ÊçÆÔºåÂπ∂‰ªé‰∏≠ÊèêÂèñÊúâÊÑè‰πâÁöÑÁîüÁâ©Â≠¶‰ø°ÊÅØ„ÄÇ

**Ê†∏ÂøÉÊÄùË∑Ø**ÔºöEXAONE Path 2.5ÁöÑÊ†∏ÂøÉÊÄùË∑ØÊòØÊûÑÂª∫‰∏Ä‰∏™Â§öÊ®°ÊÄÅÁóÖÁêÜÂ≠¶Âü∫Á°ÄÊ®°ÂûãÔºåÈÄöËøáËÅîÂêàÂª∫Ê®°ÁªÑÁªáÂ≠¶ÂõæÂÉèÂíåÂ§öÁªÑÂ≠¶Êï∞ÊçÆÔºàÂü∫Âõ†ÁªÑÂ≠¶„ÄÅË°®ËßÇÂü∫Âõ†ÁªÑÂ≠¶ÂíåËΩ¨ÂΩïÁªÑÂ≠¶ÔºâÔºåÂ≠¶‰π†‰∏Ä‰∏™ÁªºÂêàÁöÑÊÇ£ËÄÖË°®ÂæÅ„ÄÇËØ•Ê®°ÂûãÊó®Âú®ÊçïÊçâ‰∏çÂêåÁîüÁâ©Â±ÇÈù¢ÁöÑÁõ∏‰∫í‰ΩúÁî®Ôºå‰ªéËÄåÊõ¥ÂÖ®Èù¢Âú∞ÂèçÊò†ËÇøÁò§ÁöÑÁîüÁâ©Â≠¶ÁâπÂæÅ„ÄÇÈÄöËøáÂ§öÊ®°ÊÄÅÂØπÈΩêÔºåÊ®°ÂûãËÉΩÂ§üÂ∞ÜÂõæÂÉè‰ø°ÊÅØ‰∏éÂàÜÂ≠ê‰ø°ÊÅØÂÖ≥ËÅîËµ∑Êù•Ôºå‰ªéËÄåÊèêÈ´òËØäÊñ≠ÂíåÈ¢ÑÊµãÁöÑÂáÜÁ°ÆÊÄß„ÄÇ

**ÊäÄÊúØÊ°ÜÊû∂**ÔºöEXAONE Path 2.5ÁöÑÊäÄÊúØÊ°ÜÊû∂‰∏ªË¶ÅÂåÖÂê´‰∏â‰∏™ÂÖ≥ÈîÆÊ®°ÂùóÔºö1) Â§öÊ®°ÊÄÅSigLIPÊçüÂ§±ÔºöÁî®‰∫éË∑®ÂºÇÊûÑÊ®°ÊÄÅËøõË°åÊâÄÊúâÊàêÂØπÂØπÊØîÂ≠¶‰π†Ôºå‰øÉËøõ‰∏çÂêåÊ®°ÊÄÅ‰πãÈó¥ÁöÑ‰ø°ÊÅØËûçÂêà„ÄÇ2) ÁâáÊÆµÊÑüÁü•ÊóãËΩ¨‰ΩçÁΩÆÁºñÁ†ÅÔºàF-RoPEÔºâÊ®°ÂùóÔºöÁî®‰∫éÂú®ÂÖ®ÂàáÁâáÂõæÂÉèÔºàWSIÔºâ‰∏≠‰øùÁïôÁ©∫Èó¥ÁªìÊûÑÂíåÁªÑÁªáÁâáÊÆµÊãìÊâëÂÖ≥Á≥ªÔºåÊèêÈ´òÊ®°ÂûãÂØπÂõæÂÉè‰ø°ÊÅØÁöÑÁêÜËß£„ÄÇ3) È¢ÜÂüü‰∏ìÁî®ÂÜÖÈÉ®Âü∫Á°ÄÊ®°ÂûãÔºö‰∏∫WSIÂíåRNA-seqÂàÜÂà´ÊûÑÂª∫È¢ÜÂüü‰∏ì‰∏öÁöÑÂü∫Á°ÄÊ®°ÂûãÔºåÊèê‰æõÁîüÁâ©Â≠¶Âü∫Á°ÄÁöÑÂµåÂÖ•Ôºå‰ªéËÄåÂÆûÁé∞Á®≥ÂÅ•ÁöÑÂ§öÊ®°ÊÄÅÂØπÈΩê„ÄÇÊï¥‰ΩìÊµÅÁ®ãÊòØÂÖàÂØπ‰∏çÂêåÊ®°ÊÄÅÁöÑÊï∞ÊçÆËøõË°åÈ¢ÑÂ§ÑÁêÜÂíåÂµåÂÖ•ÔºåÁÑ∂ÂêéÈÄöËøáÂ§öÊ®°ÊÄÅSigLIPÊçüÂ§±ËøõË°åËÅîÂêàËÆ≠ÁªÉÔºåÊúÄÂêéÂà©Áî®ËÆ≠ÁªÉÂ•ΩÁöÑÊ®°ÂûãËøõË°å‰∏ãÊ∏∏‰ªªÂä°„ÄÇ

**ÂÖ≥ÈîÆÂàõÊñ∞**ÔºöËØ•ËÆ∫ÊñáÁöÑÂÖ≥ÈîÆÂàõÊñ∞Âú®‰∫éÂ§öÊ®°ÊÄÅËûçÂêàÁ≠ñÁï•ÂíåÁâáÊÆµÊÑüÁü•ÊóãËΩ¨‰ΩçÁΩÆÁºñÁ†Å„ÄÇ‰∏éÁé∞ÊúâÊñπÊ≥ïÁõ∏ÊØîÔºåEXAONE Path 2.5‰∏ç‰ªÖËÄÉËôë‰∫ÜÁªÑÁªáÁóÖÁêÜÂ≠¶ÂõæÂÉèÔºåËøòÊï¥Âêà‰∫ÜÂü∫Âõ†ÁªÑÂ≠¶„ÄÅË°®ËßÇÂü∫Âõ†ÁªÑÂ≠¶ÂíåËΩ¨ÂΩïÁªÑÂ≠¶Êï∞ÊçÆÔºå‰ªéËÄåÊõ¥ÂÖ®Èù¢Âú∞ÂèçÊò†ËÇøÁò§ÁöÑÁîüÁâ©Â≠¶ÁâπÂæÅ„ÄÇF-RoPEÊ®°ÂùóËÉΩÂ§üÊúâÊïàÂú∞‰øùÁïôWSI‰∏≠ÁöÑÁ©∫Èó¥‰ø°ÊÅØÔºåÊèêÈ´òÊ®°ÂûãÂØπÂõæÂÉè‰ø°ÊÅØÁöÑÁêÜËß£„ÄÇÊ≠§Â§ñÔºåÈ¢ÜÂüü‰∏ìÁî®ÂÜÖÈÉ®Âü∫Á°ÄÊ®°ÂûãËÉΩÂ§ü‰∏∫Â§öÊ®°ÊÄÅÂØπÈΩêÊèê‰æõÁîüÁâ©Â≠¶Âü∫Á°ÄÁöÑÂµåÂÖ•Ôºå‰ªéËÄåÊèêÈ´òÊ®°ÂûãÁöÑÈ≤ÅÊ£íÊÄß„ÄÇ

**ÂÖ≥ÈîÆËÆæËÆ°**ÔºöÂ§öÊ®°ÊÄÅSigLIPÊçüÂ§±ÂáΩÊï∞ÁöÑËÆæËÆ°Êó®Âú®‰øÉËøõ‰∏çÂêåÊ®°ÊÄÅ‰πãÈó¥ÁöÑ‰ø°ÊÅØËûçÂêàÔºåÈÄöËøáÂØπÊØîÂ≠¶‰π†ÁöÑÊñπÂºèÔºå‰ΩøÊ®°ÂûãËÉΩÂ§üÂ≠¶‰π†Âà∞‰∏çÂêåÊ®°ÊÄÅ‰πãÈó¥ÁöÑÂØπÂ∫îÂÖ≥Á≥ª„ÄÇF-RoPEÊ®°ÂùóÈÄöËøáÊóãËΩ¨‰ΩçÁΩÆÁºñÁ†ÅÁöÑÊñπÂºèÔºå‰øùÁïô‰∫ÜWSI‰∏≠ÁöÑÁ©∫Èó¥‰ø°ÊÅØÔºåÊèêÈ´ò‰∫ÜÊ®°ÂûãÂØπÂõæÂÉè‰ø°ÊÅØÁöÑÁêÜËß£„ÄÇÈ¢ÜÂüü‰∏ìÁî®ÂÜÖÈÉ®Âü∫Á°ÄÊ®°ÂûãÁöÑËÆæËÆ°Êó®Âú®‰∏∫Â§öÊ®°ÊÄÅÂØπÈΩêÊèê‰æõÁîüÁâ©Â≠¶Âü∫Á°ÄÁöÑÂµåÂÖ•Ôºå‰ªéËÄåÊèêÈ´òÊ®°ÂûãÁöÑÈ≤ÅÊ£íÊÄß„ÄÇÂÖ∑‰ΩìÁöÑÁΩëÁªúÁªìÊûÑÂíåÂèÇÊï∞ËÆæÁΩÆÂú®ËÆ∫Êñá‰∏≠ÊúâËØ¶ÁªÜÊèèËø∞Ôºå‰æãÂ¶Ç‰ΩøÁî®‰∫ÜTransformerÊû∂ÊûÑÔºåÂπ∂ÈíàÂØπ‰∏çÂêåÊ®°ÊÄÅÁöÑÊï∞ÊçÆÁâπÁÇπËøõË°å‰∫ÜË∞ÉÊï¥„ÄÇ

## üìä ÂÆûÈ™å‰∫ÆÁÇπ

EXAONE Path 2.5Âú®Patho-BenchÂü∫ÂáÜÊµãËØï‰∏≠ÂèñÂæó‰∫Ü‰∏éÊúÄÂÖàËøõÁöÑÂü∫Á°ÄÊ®°ÂûãÁõ∏ÂΩìÁöÑÊÄßËÉΩÔºåÂêåÊó∂Âú®ÂÜÖÈÉ®‰∏¥Â∫äÁéØÂ¢É‰∏≠Ë°®Áé∞Âá∫Êõ¥È´òÁöÑÈÄÇÂ∫îÊÄß„ÄÇËøôË°®ÊòéËØ•Ê®°ÂûãÂÖ∑ÊúâËâØÂ•ΩÁöÑÊ≥õÂåñËÉΩÂäõÂíåÂÆûÈôÖÂ∫îÁî®‰ª∑ÂÄº„ÄÇÊ≠§Â§ñÔºåËØ•Ê®°ÂûãËøòÂ±ïÁ§∫‰∫ÜÈ´òÊï∞ÊçÆÂíåÂèÇÊï∞ÊïàÁéáÔºåËøôÊÑèÂë≥ÁùÄÂÆÉÂèØ‰ª•Âú®ÊúâÈôêÁöÑÊï∞ÊçÆÂíåËÆ°ÁÆóËµÑÊ∫ê‰∏ãÂèñÂæóËâØÂ•ΩÁöÑÊÄßËÉΩ„ÄÇ

## üéØ Â∫îÁî®Âú∫ÊôØ

EXAONE Path 2.5ÂÖ∑ÊúâÂπøÊ≥õÁöÑÂ∫îÁî®ÂâçÊôØÔºåÂèØÁî®‰∫éÁôåÁóáËØäÊñ≠„ÄÅÈ¢ÑÂêéÈ¢ÑÊµã„ÄÅÊ≤ªÁñóÊñπÊ°àÈÄâÊã©ÂíåËçØÁâ©Á†îÂèëÁ≠âÈ¢ÜÂüü„ÄÇÈÄöËøáÊï¥ÂêàÂ§öÁªÑÂ≠¶Êï∞ÊçÆÔºåËØ•Ê®°ÂûãËÉΩÂ§üÊõ¥ÂÖ®Èù¢Âú∞ÁêÜËß£ËÇøÁò§ÁöÑÁîüÁâ©Â≠¶Êú∫Âà∂Ôºå‰ªéËÄåÊèêÈ´òËØäÊñ≠ÁöÑÂáÜÁ°ÆÊÄßÂíåÈ¢ÑÂêéÈ¢ÑÊµãÁöÑÂèØÈù†ÊÄß„ÄÇÊ≠§Â§ñÔºåËØ•Ê®°ÂûãËøòÂèØ‰ª•Áî®‰∫éËØÜÂà´ÊΩúÂú®ÁöÑËçØÁâ©Èù∂ÁÇπÔºåÂä†ÈÄüËçØÁâ©Á†îÂèëËøõÁ®ãÔºåÊúÄÁªàÂÆûÁé∞Á≤æÂáÜËÇøÁò§Â≠¶„ÄÇ

## üìÑ ÊëòË¶ÅÔºàÂéüÊñáÔºâ

> Cancer progression arises from interactions across multiple biological layers, especially beyond morphological and across molecular layers that remain invisible to image-only models. To capture this broader biological landscape, we present EXAONE Path 2.5, a pathology foundation model that jointly models histologic, genomic, epigenetic and transcriptomic modalities, producing an integrated patient representation that reflects tumor biology more comprehensively. Our approach incorporates three key components: (1) multimodal SigLIP loss enabling all-pairwise contrastive learning across heterogeneous modalities, (2) a fragment-aware rotary positional encoding (F-RoPE) module that preserves spatial structure and tissue-fragment topology in WSI, and (3) domain-specialized internal foundation models for both WSI and RNA-seq to provide biologically grounded embeddings for robust multimodal alignment. We evaluate EXAONE Path 2.5 against six leading pathology foundation models across two complementary benchmarks: an internal real-world clinical dataset and the Patho-Bench benchmark covering 80 tasks. Our framework demonstrates high data and parameter efficiency, achieving on-par performance with state-of-the-art foundation models on Patho-Bench while exhibiting the highest adaptability in the internal clinical setting. These results highlight the value of biologically informed multimodal design and underscore the potential of integrated genotype-to-phenotype modeling for next-generation precision oncology.

